Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Short Interest Update

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) was the target of a large growth in short interest in December. As of December 31st, there was short interest totalling 3,840,000 shares, a growth of 8.2% from the December 15th total of 3,550,000 shares. Based on an average trading volume of 463,300 shares, the short-interest ratio is currently 8.3 days.

Institutional Investors Weigh In On Aldeyra Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Perceptive Advisors LLC grew its position in Aldeyra Therapeutics by 7.9% in the 2nd quarter. Perceptive Advisors LLC now owns 9,275,851 shares of the biotechnology company’s stock valued at $30,703,000 after acquiring an additional 682,265 shares during the last quarter. Federated Hermes Inc. bought a new position in shares of Aldeyra Therapeutics in the second quarter worth about $1,758,000. Jacobs Levy Equity Management Inc. increased its stake in Aldeyra Therapeutics by 163.4% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 476,949 shares of the biotechnology company’s stock worth $2,571,000 after buying an additional 295,864 shares during the period. International Assets Investment Management LLC lifted its holdings in Aldeyra Therapeutics by 397.0% during the 3rd quarter. International Assets Investment Management LLC now owns 287,287 shares of the biotechnology company’s stock valued at $15,480,000 after buying an additional 229,487 shares in the last quarter. Finally, Barclays PLC grew its stake in Aldeyra Therapeutics by 280.1% in the 3rd quarter. Barclays PLC now owns 65,561 shares of the biotechnology company’s stock worth $353,000 after acquiring an additional 48,313 shares in the last quarter. 59.71% of the stock is currently owned by hedge funds and other institutional investors.

Aldeyra Therapeutics Price Performance

Shares of ALDX opened at $4.84 on Monday. The company has a debt-to-equity ratio of 0.18, a quick ratio of 6.80 and a current ratio of 6.80. The business has a fifty day moving average of $4.94 and a 200 day moving average of $4.98. Aldeyra Therapeutics has a 52-week low of $2.71 and a 52-week high of $6.55.

Aldeyra Therapeutics (NASDAQ:ALDX) last released its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.25) EPS for the quarter, hitting analysts’ consensus estimates of ($0.25). On average, research analysts predict that Aldeyra Therapeutics will post -0.92 EPS for the current fiscal year.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.